Methylhomatropine: Side Effects, Uses & Monitoring

Hydrocodone bitartrate and homatropine methylbromide oral solution is indicated for the symptomatic relief of cough in adult patients 18 years of age and older.

Data source
FDA labeling via NIH DailyMed (label a324c912…)
Label version
current
Last reviewed
2026
Side effects

Reported adverse reactions

Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.

No structured frequency data available in current labeling. Consult the official label.

Uses

Labeled uses (from FDA prescribing information)

Hydrocodone bitartrate and homatropine methylbromide oral solution is indicated for the symptomatic relief of cough in adult patients 18 years of age and older. Limitations of Use: Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4 )] . Contraindicated in pediatric patients less than 6 years of age [see Contraindications (4 )] . Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy [see Warnings and Precautions (5.1 )] , reserve hydrocodone bitartrate and homatropine methylbromide oral solution for use in adult patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of cough.

FAQ

Frequently Asked Questions

What is Methylhomatropine used for?

FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.

What are the most commonly reported side effects of Methylhomatropine?

Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.

Does Methylhomatropine require lab monitoring?

Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Methylhomatropine.

Where does this information come from?

All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.

Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

Educational content only: The information on Symptom Database.com is for educational purposes and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Read our full disclaimer.